Steven Seedhouse
Stock Analyst at Raymond James
Total Price Targets
7
Stocks Covered
6
Sectors
Consumer Cyclical, Energy, Healthcare
Most Recent
Dec 11, 2025
Notable Calls (Last 12 Months)
Stocks Covered by Steven Seedhouse
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| MIRM | Mirum Pharmaceuticals, Inc. | $110.00 | $97.47 | +12.9% | 1 | Dec 11, 2025 |
| GILD | Gilead Sciences, Inc. | $93.00 | $132.04 | -29.6% | 1 | Jul 8, 2024 |
| SEDG | SolarEdge Technologies, Inc. | $93.00 | $42.19 | +120.4% | 1 | Jul 8, 2024 |
| DNTH | Dianthus Therapeutics, Inc. | $51.00 | $87.86 | -42.0% | 1 | Apr 18, 2024 |
| KMX | CarMax, Inc. | $35.00 | $38.62 | -9.4% | 1 | Dec 23, 2022 |
| NTLA | Intellia Therapeutics, Inc. | $105.00 | $13.20 | +695.5% | 2 | May 9, 2022 |
Recent Activity
- Dec 11, 2025— Set$110.00price target onMIRM(Mirum Pharmaceuticals, Inc.)
- Jul 8, 2024— Set$93.00price target onGILD(Gilead Sciences, Inc.)
- Jul 8, 2024— Set$93.00price target onSEDG(SolarEdge Technologies, Inc.)
- Apr 18, 2024— Set$51.00price target onDNTH(Dianthus Therapeutics, Inc.)
- Dec 23, 2022— Set$35.00price target onKMX(CarMax, Inc.)
- May 9, 2022— Set$105.00price target onNTLA(Intellia Therapeutics, Inc.)
- Aug 6, 2021— Set$181.00price target onNTLA(Intellia Therapeutics, Inc.)
Frequently Asked Questions
Who is Steven Seedhouse?
Steven Seedhouse is a stock analyst at Raymond James covering 6 stocks primarily in Consumer Cyclical, Energy, Healthcare. They have issued 7 price targets since Aug 6, 2021.
What stocks does Steven Seedhouse cover?
Steven Seedhouse currently covers 6 stocks, including NTLA, MIRM, GILD, SEDG, DNTH.
What is Steven Seedhouse's latest price target?
Steven Seedhouse's most recent price target was $110.00 on MIRM (Mirum Pharmaceuticals, Inc.), set on Dec 11, 2025.
What is Steven Seedhouse's highest price target?
Steven Seedhouse's highest issued price target is $181.00 on NTLA, set on Aug 6, 2021.
More Analysts at Raymond James
Coverage based on publicly published price targets. Not investment advice.